Showing posts with label hormone receptive negative breast cancer. Show all posts
Showing posts with label hormone receptive negative breast cancer. Show all posts

Tuesday, April 21, 2009

Zometa: Not Proven for Hormone-Negative

Zometa (zoledronic acid) has been touted as a life-saving drug, based on research in the February New England Journal of Medicine.    And it looks like the drug has serious potential—for women with hormone-positive disease.  Some things for women with hormone-negative breast cancer, including triple negative, to consider:

• The women studied were all premenopausal who were hormone-positive and were given hormonal therapy—either tamoxifen or Arimidex—plus goserelin (Zoladex) to suppress ovarian function.

• None received adjuvant (after surgery) chemotherapy;

The study found a 98 percent chance of survival in young women who were given ovarian suppression and hormone therapy drugs but did receive any chemotherapy.

So this could be great news for a narrow group of women.  Unfortunately, this does not include those of us with hormone-negative disease.

The Dr. Susan Love Research Foundation has a great analysis of this

Back to the drawing board, docs.  Find us a cure.

(My thanks to the talented Deb Lattimore for sending me Dr. Love’s link.  You can read about Deb’s fight against triple negative, and enjoy her excellent photography, here. )

 

Saturday, September 13, 2008

Risk of Late Recurrence Lower for Hormone Negative

Here’s a good news/better new flash: women with early stage breast cancer remain at low risk of recurrence years after treatment. That’s good. Better is that women with hormone negative cancers face a much smaller risk of later recurrence than those with hormone positive. This, despite the fact that hormone negative is considered to be more lethal than positive.

The study, by researchers at the University of Texas M.D. Anderson Cancer Center, included 2,838 women with stage I, II, or III breast cancer between 1985 and 2001. Five years after beginning therapy—chemotherapy, radiation, tamoxifen or all three—those with hormone negative disease faced a seven percent chance of recurrence, while those with hormone positive had a 13 percent chance.

The really good news: 89 percent of all patients had no recurrences within 10 years; 80 percent had no recurrences after 15 years. Within five years, those with stage I cancer had a 7 percent risk of recurrence; stage II faced an 11 percent risk; and stage III faced a 13 percent risk.

The research was published online in the Journal of the National Cancer Institute on August 11, 2008. Because HER2 was not routinely measured at the time and Herceptin and aromotase inhibitors had not been introduced, they were not included in the data. Until 2000, tamoxifen was the only drug for follow-up breast cancer care, and it was limited to women with hormone positive disease.

Researchers say that, while the numbers are small, the fact that cancer can recur years after therapy points to a need for more follow-up care. An interesting conundrum, considering the fact that women with hormone negative cancer faced a lower rate of late recurrence than women with hormone positive disease. That is, women for whom there never has been a long-term drug treatment option did better than women with the drug.

The study does point to continued need for regular follow-up exams and mammograms. I would also emphasize the importance of focusing on a low-fat, healthy diet with plenty of exercise, which have been proven to lower the risk of recurrence of hormone negative breast cancer.

Sunday, May 18, 2008

Exercise—the best medicine for hormone-negative

Physical activity, including moderate walks and cycling, reduces the risk of breast cancer, with the greatest benefit among women who are hormone-negative, according to a literature review of 62 studies on the effect of exercise on breast cancer risk. Other women whose gains are especially significant: non-whites, those with a family history of breast cancer, and those who have given birth to two or more children benefit the most from exercise.

The review, published in the May 13 edition of the British Journal of Sports Medicine, found that:

• In 76 percent of the studies, physically active women had a lower breast cancer risk; risk reduction was significant in 30 of the 62 studies.

• Among the studies that showed an effect, breast cancer risk was reduced by an average of 25 percent.

• Moderate activity such as walking or leisure cycling brought better odd—a 26 percent reduction—than high intensity exercise—a 22 percent reduction.

• Lifetime activity showed the greatest benefit—greater than that from activity around the time of diagnosis.

• Active postmenopausal women benefit the most. Activity over age 50 showed a greater risk reduction that activity in adolescence and early childhood.

• Thin is best, but only when associated with exercise. Women with a BMI of less than 22 had 19 percent greater risk reduction than women with a BMI above 25. (See the link on the left to compute your BMI.)

• A high BMI cuts the effect. Women with a BMI over 30, even if they are active, had no risk reduction from exercise.

Please consider a donation to Positives About Negative to keep this site going.  This work is entirely supported by readers.  Just click on the Donate button in the right of the page.  Thank you!


Read more about TNBC in my book, Surviving Triple-Negative Breast Cancer.

Sunday, May 11, 2008

Carbohydrates increase hormone-negative breast cancer risk

A diet heavy in simple carbohydrates—sugar, white bread, cakes and cookies—can put a woman at risk of hormone-receptor-negative breast cancer, according to research in the American Journal of Nutrition’s May 2008 issue. French researchers studied the diets of 62,739 postmenopausal women from 1993 to 2002; 1812 of these women eventually were diagnosed with breast cancer. The researchers note that, because simple carbs are rapidly absorbed by the body, they elevate insulin levels, which can be the link to hormone-receptor-negative breast cancer. According the Centers for Disease Control, complex carbohydrates—whole grains, seeds, vegetables and most fruits—are more slowly digested and less likely to increase insulin levels.

Wednesday, April 30, 2008

Hormone-Negative Rates Drop; Benefits of Vitamin D

The American Association of Cancer Research met earlier this month in San Diego. Several studies dealt with hormone-negative breast cancer. I highlight a couple of them below.

Estrogen-negative cases drop slightly for most women
Cases of estrogen-receptor-negative breast cancer dropped slightly for white and Hispanic women between 2002 and 2004, but rose for African-Americans, according to researchers from the University of Chicago Medical Center.

Estrogen-negative disease disproportionately affects black women, with 40 percent of their tumors likely to be estrogen-negative compared to 20 percent for white or Hispanic women. And while blacks are less likely to get cancer in the first place, they are more likely to be diagnosed with advanced and more lethal forms, such as triple negative (ER-, PR- and HR2-).

Estrogen-receptor-positive breast cancers also dipped, notably among women 50 to 69, with a 13% drop for whites, 11% for Hispanics, 4% for Asian or Pacific Islanders, but no change for African-Americans. This was tied to a reduction in the use of hormone replacement therapy, which affects estrogen-positive cases because they are fueled by hormones.

The reduction in hormone-negative does not have the logical link to HRT and researchers did not explain the drop in those cases. They speculate that black women may have less access to regular mammograms, which accounts for their tumors being at an advanced stage at diagnosis.

Environmental and social factors may also influence cancer, with women in Nigeria having estrogen-receptor positive tumors 70 percent of the time—a 43 percent increase over African-Americans.


Vitamin D Slows Breast Cancer in Rats
A specific form of active vitamin D known as Gemini 0097 substantially reduced the development of both estrogen-negative and estrogen-positive breast cancer in rats. Researchers at Rutgers University injected rats with breast cancers then treated them with Gemini 0097. The vitamin D slowed the growth of ER-positive by 60 percent and ER-negative by 50 percent.

As with all studies in animals, more research needs to be done to determine the effects of Gemini 0097 on human cancers. One benefit so far is that Gemini 0097 is less toxic than other forms of synthetic vitamin D and does not lead to an overload of calcium, the most common side-effect.

Tuesday, March 11, 2008

My Stats and My Story

When my gynecologist found my tumor, she said it was small and probably nothing to worry about. This was on a Friday, and my mammogram was on a Monday. In the middle was Mother’s Day. I did not worry about the lump. I figured I was OK.

But the radiologist thought otherwise. She looked at my mammogram, then did a sonogram. She kept poking and probing, talking about some television show—I cannot remember which one—to keep my mind off what it appeared she was finding. She pulled no punches and told me she was pretty sure the pathology report would come back showing “something abnormal.”

That night, I hit the Internet and found a variety of studies that showed that most breast lumps were not cancerous, so once again I decided I was OK. I wasn’t. This was becoming a lousy pattern.

The radiologist called and told me the bad news, but said my tumor was small, telling me, “Patricia, this is not that bad.” I wonder if she has any idea how often I still think of those reassuring words.

I got little reassurance in the ensuing days, but I did get a lot of confusion, starting with the size of my tumor. Breast tumors are measured a variety of ways. First, there’s the size from the sonogram. Mine was 1.5 cm at that point. There’s also the size from the mammogram; mine was 2.1 there. Then there’s the size the pathologist determines after surgery by measuring the tumor itself. Mine was 1.3 X 1.1 cm at that point. This is a big deal, as tumors under 2 cm are considered Stage 1, or early stage.

Then I began meeting with the docs.

At my first meeting with the surgeon, he told me that I had an invasive ductal carcinoma—the cancer had broken through the wall of the milk duct and invaded other tissue. He said I would have a lumpectomy—an elegant lay term for a partial mastectomy—and radiation, unless the cancer had spread. Only if it had spread would I need chemo, he said. At this point I knew nothing about hormone negative cancer, so I asked few questions, and trustingly made plans for the surgery. I somehow knew it had not spread and so I figured I would have the inconvenience of radiation, but that was it.

Wrong again.

The surgeon explained that he would take out only one lymph node—the sentinel node, or the node to which the cancer would move. This is determined by injecting a radioactive tracer consisting of blue dye into my tumor and seeing where it moves. The node to which it heads first is the sentinel node.

He ended up taking out two sentinel nodes, both of which were negative, thank God. The cancer had not spread. He told me this immediately after surgery, while I was still in recovery. Then he quietly dropped a bombshell. He told me he got all the cancer—with a healthy, clear .3cm margin—but that he wanted me to see an oncologist about chemo. “But it has not spread; I don’t need chemo,” I argued. He was adamant. His nurse would set up the appointment.

It was not until my husband and I naively went into the Oncologist Number One’s office a week after surgery that I learned that there was such a thing as hormone-negative cancer and that it is more aggressive than hormone positive. I was estrogen-negative, weakly positive for progesterone and negative for Her2. The oncologist said they treat that weakly positive as negative and that I needed chemo because of the aggressive nature of my tumor.

He said the tumor was poorly differentiated, which meant it could grow rapidly. And he said it was 2.1 centimeters, making it a Stage II rather than a Stage I. He used the size from the mammogram. Had I gone with his interpretation, I would have had four rounds of adriamycin and cytoxen followed by four rounds of taxol, or 16 weeks of chemotherapy.

I had 100 percent chance of losing my hair after two weeks of treatment, he said, but nausea and vomiting are “no longer an issue” because of drugs. He said I would not feel 100 percent normal, but could count on being about 85 percent of my charming self. The taxol, he said, might cause some degeneration of nerves, but it goes away with time. He was so calm and cool and officious, I wish I had asked if he had ever had chemo.

My husband and I left the office in shock. Chemo put an entirely different color on the whole thing. When you lose your hair, you are a cancer patient, with a capital “C.” Without chemo, it is lower-case cancer.

After reeling for a few hours, I decided to get a second opinion, but I was still depending on the advice of doctors; I had not yet done research into hormone-negative cancer. Magically, I ultimately made the right decisions, but I wish I had been better informed from the beginning.

We met with Oncologist Number Two three days later. He looked through the chart and said the tumor was only 1.1 cm—what the pathologist determined after surgery. It wasn’t very big and it had not spread, so it was early stage breast cancer. But it was hormone-negative and therefore very aggressive. “This is a young woman’s cancer,” he said. “We take it very seriously. You don’t get a second chance.” However, because my nodes were negative, he said I would need the adriamycin and cytoxen in a dose-dense regimen every two week, but I would not need the taxol. I would then have radiation.

And he looked at the Nottingham Histologic Score, which was Grade II, meaning it was in the mid-range in terms of aggressiveness. The higher the grade, the more aggressive the tumor: Grade I is slow growing; Grade III is fast growing. I felt a little calmer, knowing I was middle-of-the-road.

I went with Oncologist Two and his regimen, which, I learned through research, is the standard for early-stage node-negative hormone-receptor-negative cancer. So many negatives, and I was trying so hard to be positive.

I had four rounds of chemotherapy—adriamycin and cytoxan—and I did, indeed lose my hair. Three weeks after chemo started, just as Oncologist Two predicted.

But the business about no nausea from Oncologist Number One? Well, we took him seriously, and went out for lunch after the first chemo treatment. I still cannot look at spaghetti with meat sauce without a sense of revulsion. Ick. I learned to eat small, mild meals before chemo and the nausea was better, but I still felt ill the day or two after treatment. I also started visiting an acupuncturist on the day of treatment and that helped the nausea and my well being immensely. I still see her. I think she is magic.

I continued walking for exercise throughout treatment. That, I think, helped the nausea. I worked as much as I could, often at home, and found the frustrations of academic life to be a nice reprieve from cancer treatment. Cancer does put everything into perspective. I had a thoroughly supportive workplace, which was a blessing and, I am sure, helped my recovery.

After chemo, I had 33 days of radiation. Every weekday for six and a half weeks. I loved my radiation oncologist—a truly positive woman—and the technicians, who all had a good attitude and a sense of humor.

I began this adventure May 15 with the mammogram, sonogram and biopsy. I had surgery exactly two weeks later, on May 29. Chemo went from June 16 through July 27. Radiation started August 14 and ended September 29.

On October 7, two weeks after my last radiation treatment, I was hiking in the Colorado Rockies. My longest hike that year was a three-hour trek up to 9,000 feet. As I walked I enjoyed the warm autumn sun, the purple mountains, the orange and gold fall leaves, and I thought of how I loved this part of my world. We walked briskly and I had no trouble keeping up with my husband, brother and nephew, all usually stronger hikers than me. It wasn’t until I reached the top of a canyon and asked my husband to take a picture of me with my still-bald head that I remembered I had just finished cancer treatment. It all seemed like a bad dream. Or perhaps, a good one. I had, in fact, awakened, with energy and sprit and, most important, health.

Wednesday, March 5, 2008

Oncotype DX test minimal help for hormone-receptor-negative

The Oncotype DX test can predict the likelihood of recurrence in early stage invasive breast cancer, but it has one flaw: It works with hormone-positive cancers, not hormone-negative. Once again we’re the wallflowers at the breast cancer prom, with the docs dancing with the girls with the popular cancer.

Still, the test might be worth asking for (check to see if your insurance covers it first) because it will include your estrogen (ER) and progesterone (PR) receptor status. This is factored into the likely rate of recurrence and is used to determine the potential benefit of chemotherapy and tamoxifen.

A sample test nicely demonstrates how pathologists define ER and PR scores. The higher you are in the positive range, the more you will benefit from tamoxifen. I did not have a graph like this to clarify my readings. I just got a generic “ER-negative; PR weakly positive” statement. When I finally came to my senses and realized I needed more data, I called the lab to determine how weakly positive I was. They said they no longer had the sample and had just the information I already had on my pathology report. They gave me their definition of “negative” as being less than 50 percent of the sample. It would have been great to have had the additional data this test provides, even if it could not determine the rate of recurrence of my cancer.

My husband, though, reminds me often: My cancer is not coming back. Period.   

Sunday, March 2, 2008

Newly Diagnosed with Hormone Negative? Where to Start?

Try to remain positive.  Look at this: Overall 86.8 percent of patients with hormone-negative tumors were disease-free ten years after diagnosis, according to research presented at the Fifth European Breast Cancer Conference . This comes even with some advanced cancers. Of those survivors with hormone-negative tumors who were disease-free after five years, 35 percent had had lymph node involvement, and 11 percent had grade 3 tumors.

So focus on survival and taking care of yourself right now. Some tips on doing that:

• Get your pathology report. Thebreastcaresite.com has some great information on how to understand it. Dr. Susan Love's Breast Book also offers a comprehensive explanation. The report is where you will learn your hormone receptor status, plus the size of your tumor and how aggressive it is. You can get your report from any of your doctors. Get is as soon as you are diagnosed, read it carefully, and ask your doctors to explain what you don’t understand.

• Plan on chemo. It works. Newer forms (high-doses of cytoxan and adriamycin every two weeks plus taxol) are especially effective, according to research published in the Journal of the American Medical Association. This regimen reduced the risk of death by 55 percent as compared with older forms (low-doses of cytoxan and adriamycin plus fluorouracil every three weeks) in women with hormone-negative cancer that had spread to the lymph nodes. Typically, women whose cancer has not spread to the lymph nodes do not need taxol.

• Get your body in shape. Exercise helps reduce the risk of recurrence, improves your mood throughout treatment, and keeps you from gaining weight during chemotherapy. Weight gain during chemo? Yes, that is sort of adding insult to injury but it is true. In a study in the Journal of Clinical Oncology of 514 breast cancer survivors three years after diagnosis, 68 percent gained an average of 8.6 pounds, with a maximum increase of 60 pounds. Women treated with chemotherapy gained the most, adding an average of 4 percent to their pre-diagnosis weight.

• Get your mind in shape. Being positive makes this all a lot easier. Look to family and friends for support, be open to what they give, and be patient with their occasional stumbles. This is new and stressful for them too. If you’re the least bit religious, remember the importance of prayer. I’ve written on how prayer helped me . Meditation and yoga can also help you maintain your sanity. Its basic emphasis: balance.

• Go outside. ”Natural intervention,” or spending two hours a week in nature watching birds, tending to plants or gardens, sitting by a window with a view of trees or a garden can cut the fatigue that is often associated with cancer treatment.

• Watch your diet. Women with hormone negative benefited the most from a low-fat diet, with a 42 percent reduction in recurrence, according research in the Journal of the National Cancer Institute.

• Before surgery, check into brachytherapy instead of standard radiation. It cuts radiation time from five or six weeks to one, and it is far less invasive. Doctors embed radiation seeds into the breast, so this needs to be coordinated with your surgeon. I waited too late to ask for it and my wound had already healed, so I had to go the traditional route.

• Consider acupuncture. It can help ease the nausea of chemo and it can you relax and find peace. I visited my acupuncturist before each treatment and she made me feel calmer, no matter what.

• Live your life. Your chances of that life being a normal length are far better than you might think right now. Continue doing what you did before, only try to make it a little healthier.